Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)

NCT ID: NCT02688985

Last Updated: 2024-06-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 131 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-04-29
• Study Completion Date: 2023-04-11

Brief Summary

This is an open-label, multicenter, biomarker study designed to be hypothesis-generating in order to better understand the mechanism of action of ocrelizumab and B-cell biology in RMS or PPMS. The study will be conducted in two cohorts i.e. RMS cohort (4 arm group) and PPMS cohort (one arm group). RMS cohort: Ocrelizumab will be administered as two intravenous (IV) infusions of 300 milligrams (mg) on Days 1 and 15. Subsequent doses will be given as single 600-mg infusions at Weeks 24 and 48. Participants will be randomized in 1:1:1 ratio to receive lumbar puncture (LP) post-treatment at Week 12, 24, or 52 following the first dose of ocrelizumab in three arm groups. A fourth RMS arm with delayed treatment start (Arm 4 [control group]) will not be a part of the randomization and will be recruited separately, wherein treatment with ocrelizumab will be delayed for 12 weeks from pre-treatment baseline. PPMS cohort: Ocrelizumab 600 mg will be administered as two 300-mg IV infusions separated by 14 days at a scheduled interval of every 24 weeks. Participants will receive a LP at the start of the study before dosing with ocrelizumab and second LP at Week 52 following the first dose of ocrelizumab. A long-term extension will be conducted for participants that complete the study and continue to receive ocrelizumab. Treatment with ocrelizumab in the entire study will continue for approximately 4.5 years after the first infusion.

Conditions

Relapsing Multiple Sclerorsis; Multiple Sclerosis, Primary Progressive

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

RMS Cohort Arm 1: Ocrelizumab + LP

Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP before the start of dosing (Week 1, treatment baseline) with ocrelizumab and a second LP at Week 12. Participants will be asked to have an additional optional LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.

Group Type: EXPERIMENTAL

Ocrelizumab

Intervention Type: DRUG

Ocrelizumab will be administered as IV infusion.

Lumbar Puncture

Intervention Type: PROCEDURE

Participants will receive LP as specified in individual arms. Lumbar puncture is optional at week 52, except for RMS Cohort Arm 3 and PPMS Cohort. In addition, the lumbar punctures in the Long Term Extension phase is every other year.

Methyloprednisolone

Intervention Type: DRUG

Participants will receive 100 mg of IV methylprenisolone (or an equivalent) prior to ocrelizumab infusion.

Antihistamine

Intervention Type: DRUG

Participants will receive an antihistamine, such as diphenhydramine, prior to ocrelizumab infusion.

RMS Cohort Arm 2: Ocrelizumab + LP

Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP before the start of dosing (Week 1, treatment baseline) with ocrelizumab and a second LP at Week 24. Participants will be asked to have an additional optional LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.

Group Type: EXPERIMENTAL

Ocrelizumab

Intervention Type: DRUG

Ocrelizumab will be administered as IV infusion.

Lumbar Puncture

Intervention Type: PROCEDURE

Participants will receive LP as specified in individual arms. Lumbar puncture is optional at week 52, except for RMS Cohort Arm 3 and PPMS Cohort. In addition, the lumbar punctures in the Long Term Extension phase is every other year.

Methyloprednisolone

Intervention Type: DRUG

Participants will receive 100 mg of IV methylprenisolone (or an equivalent) prior to ocrelizumab infusion.

Antihistamine

Intervention Type: DRUG

Participants will receive an antihistamine, such as diphenhydramine, prior to ocrelizumab infusion.

RMS Cohort Arm 3: Ocrelizumab + LP

Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP before the start of dosing (Week 1, treatment baseline) with ocrelizumab and a second LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.

Group Type: EXPERIMENTAL

Ocrelizumab

Intervention Type: DRUG

Ocrelizumab will be administered as IV infusion.

Lumbar Puncture

Intervention Type: PROCEDURE

Participants will receive LP as specified in individual arms. Lumbar puncture is optional at week 52, except for RMS Cohort Arm 3 and PPMS Cohort. In addition, the lumbar punctures in the Long Term Extension phase is every other year.

Methyloprednisolone

Intervention Type: DRUG

Participants will receive 100 mg of IV methylprenisolone (or an equivalent) prior to ocrelizumab infusion.

Antihistamine

Intervention Type: DRUG

Participants will receive an antihistamine, such as diphenhydramine, prior to ocrelizumab infusion.

RMS Cohort Arm 4: Ocrelizumab + LP

Ocrelizumab treatment will be delayed for 12 weeks from pre-treatment baseline. Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP at Week -12 (pre-treatment baseline) and a second LP before the start of dosing (Week 1, treatment baseline). Participants will be asked to have an additional optional LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.

Group Type: EXPERIMENTAL

Ocrelizumab

Intervention Type: DRUG

Ocrelizumab will be administered as IV infusion.

Lumbar Puncture

Intervention Type: PROCEDURE

Participants will receive LP as specified in individual arms. Lumbar puncture is optional at week 52, except for RMS Cohort Arm 3 and PPMS Cohort. In addition, the lumbar punctures in the Long Term Extension phase is every other year.

Methyloprednisolone

Intervention Type: DRUG

Participants will receive 100 mg of IV methylprenisolone (or an equivalent) prior to ocrelizumab infusion.

Antihistamine

Intervention Type: DRUG

Participants will receive an antihistamine, such as diphenhydramine, prior to ocrelizumab infusion.

PPMS Cohort: Ocrelizumab + LP

For the PPMS cohort, ocrelizumab will be administered as two 300-mg IV infusions separated by 14 days at a scheduled interval of every 24 weeks during the treatment period and then as a single 600-mg dose every 24 weeks starting week 72 during the Long-Term Extension period.

Group Type: EXPERIMENTAL

Ocrelizumab

Intervention Type: DRUG

Ocrelizumab will be administered as IV infusion.

Lumbar Puncture

Intervention Type: PROCEDURE

Participants will receive LP as specified in individual arms. Lumbar puncture is optional at week 52, except for RMS Cohort Arm 3 and PPMS Cohort. In addition, the lumbar punctures in the Long Term Extension phase is every other year.

Methyloprednisolone

Intervention Type: DRUG

Participants will receive 100 mg of IV methylprenisolone (or an equivalent) prior to ocrelizumab infusion.

Antihistamine

Intervention Type: DRUG

Participants will receive an antihistamine, such as diphenhydramine, prior to ocrelizumab infusion.

Interventions

Ocrelizumab

Ocrelizumab will be administered as IV infusion.

Intervention Type: DRUG

Lumbar Puncture

Participants will receive LP as specified in individual arms. Lumbar puncture is optional at week 52, except for RMS Cohort Arm 3 and PPMS Cohort. In addition, the lumbar punctures in the Long Term Extension phase is every other year.

Intervention Type: PROCEDURE

Methyloprednisolone

Participants will receive 100 mg of IV methylprenisolone (or an equivalent) prior to ocrelizumab infusion.

Intervention Type: DRUG

Antihistamine

Participants will receive an antihistamine, such as diphenhydramine, prior to ocrelizumab infusion.

Intervention Type: DRUG

Other Intervention Names

RO4964913

Eligibility Criteria

Inclusion Criteria

• For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of <1 percent (%) per year during the treatment period and for at least 24 weeks after the last dose of study treatment or until their B-cells have repleted, whichever is longer

• Diagnosis of RMS in accordance with the 2010 revised McDonald criteria
• Expanded Disability Status Scale (EDSS) score of 0 to 5.5 points, inclusive, at Screening
• Disease duration from the onset of multiple sclerosis symptoms less than (<) 15 years in participants with an EDSS score greater than (>) 5.0 at Screening
• Either treatment-naive or receiving treatment with disease-modifying therapies, including prior use of interferon (IFN)-beta-1a (Avonex®, Rebif®), IFN-beta-1b (Betaseron®/Betaferon), or glatiramer acetate (Copaxone®).
• At least one clinically documented relapse in the past year and/or at least one T1-weighted Gadolinium (Gd)-enhancing lesion in the past year and/or at least one new T2 lesion in the past year at the time of enrollment

• Separate signed Informed Consent Form for the RMS Delayed Time to Start Control Arm (Arm 4)
• Must be willing to remain on the same dose and regimen of current standard of care, or no treatment if treatment-naïve, for 12 weeks after study enrollment The treating and/or study physician must agree that the participant is eligible to remain on the same dose and regimen of their current standard of care at Screening, or to receive no treatment if the participant is treatment-naïve, for 12 weeks after study enrollment

• Diagnosis of PPMS in accordance with the 2010 revised McDonald criteria
• EDSS score of 3.0 - 6.5 points, inclusive, at Screening
• Disease duration from the onset of multiple sclerosis symptoms <10 years in participants with an EDSS at Screening less than or equal to (</=) 5.0
• Documented history of either elevated immunoglobulin G (IgG) Index or one or more IgG oligoclonal bands (OCBs) detected by isoelectric focusing

Exclusion Criteria

• Diagnosis of secondary progressive multiple sclerosis without relapses for at least 1 year
• History or known presence of recurrent or chronic infection (e.g., human immunodeficiency virus [HIV], syphilis, tuberculosis)
• History of recurrent aspiration pneumonia requiring antibiotic therapy
• History of cancer, including solid tumors and hematological malignancies (except basal cell, in situ squamous cell carcinomas of the skin, and in situ carcinoma of the cervix of the uterus that have been excised and resolved with documented clean margins on pathology)
• History of or currently active primary or secondary immunodeficiency
• History of coagulation disorders
• History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
• History of alcohol or other drug abuse within 24 weeks prior to enrollment
• Known presence or history of other neurologic disorders Significant, uncontrolled disease, such as cardiovascular (including cardiac arrhythmia), pulmonary (including chronic obstructive pulmonary disease), renal, hepatic, endocrine, gastrointestinal, or any other significant disease
• Congestive heart failure (according to New York Heart Association III or IV functional severity)
• Known active bacterial, viral, fungal, mycobacterial infection, or any major episode of infection requiring hospitalization or treatment with IV antibiotics
• Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
• Contraindications or intolerance to oral or IV corticosteroids, including IV methylprednisolone, according to the country label
• Contraindication for LP
• Previous treatment with B cell-targeted therapies (such as rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab)
• Previous treatment with natalizumab/Tysabri®, alemtuzumab, anti-CD4 agents, cladribine, teriflunomide, cyclophosphamide, mitoxantrone, azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, total body irradiation, or bone marrow transplantation
• Treatment with fingolimod/Gilenya®, dimethyl fumarate/Tecfidera®, or similar treatment within 6 months prior to enrollment
• Receipt of a live vaccine within 6 weeks prior to enrollment
• Systemic corticosteroid therapy within 4 weeks prior to Baseline
• Previous or concurrent treatment with any investigational agent or treatment with any experimental procedure for multiple sclerosis (such as treatment for chronic cerebrospinal venous insufficiency)
• Certain laboratory abnormalities or findings at Screening
• Inability to complete an MRI
• Lack of peripheral venous access
• Pregnant or lactating, or intending to become pregnant during the study

• Diagnosis of PPMS or secondary progressive multiple sclerosis without relapses

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Genentech, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Stanford University

Palo Alto, California, United States

University of California at San Francisco

San Francisco, California, United States

University Of Colorado

Aurora, Colorado, United States

Yale University School of Medicine ; Pulmonary & Critical Care

New Haven, Connecticut, United States

University of Massachusetts Medical School

Worcester, Massachusetts, United States

Washington University; Wash Uni. Sch. Of Med

St Louis, Missouri, United States

Empire Neurology, PC

Latham, New York, United States

Weill Cornell MC-NY Presbyter; Dept. of Neurology/Neuroscience, Judith Jaffe Multiple Sclerosis Ctr

New York, New York, United States

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, United States

Ohio State University

Columbus, Ohio, United States

Oklahoma Medical Research Foundation; MS Center of Excellence

Oklahoma City, Oklahoma, United States

University of Texas Southwestern Medical Center

Dallas, Texas, United States

University of British Columbia Hospital Site; Djavad Mowafaghian Centre for Brain Health

Vancouver, British Columbia, Canada

McGill University; Montreal Neurological Institute; Neurological and Psychiatric

Montreal, Quebec, Canada

Universitätsklinikum "Carl Gustav Carus" der Technischen Universität Dresden

Dresden, , Germany

Universitätsmedizin Göttingen Georg-August-Universität

Göttingen, , Germany

Karolinska Universitetssjukhuset, Solna

Stockholm, , Sweden

Countries

United States; Canada; Germany; Sweden

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

2015-004616-37

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

ML29966

Identifier Type: -

Identifier Source: org_study_id